Maxime Verhoeven

25 Systematic review of remission-induction strategies in early RA Table 1 (continued) First author, publication year, reference Design Age in yrs. (SD) Female (%) RF+ (%) HAQ score (SD) Symptom duration in weeks (SD) DAS28 (SD) single csDMARD- initiating strategy N in single csDMARD- initiating strategy Remission- induction strategy N in remission- induction strategy Time of assess- ments in yrs. Treatment characteris- tics (both arms) Combination csDMARD based remission-induction strategy versus single csDMARD-initiating strategy without GC bridging Brunekreef, 2017 23 Cohort 59 (14) 62 65 § § § MTX 297 MTX+HCQ+GCim 156 1 T2T IM 80-120mg Ma, 2014 24 RCT 54( § ) 68 87 1.6 ( § ) § 5.8 (1.3) MTX 87 CSA+MTX+GC 90 2 T2T bridg. 34w Rannio, 2017 25 Cohort 57 (16) 67 71 0.9 ( § ) 24 ( § ) 4.2 (1.4) MTX(+GC) 453 MTX+ SSZ+HCQ 158 1 T2T Steunebrink, 2016 26 2 cohorts 59 (13) 62 54 1.1( § ) § 4.7 (1.1) MTX+PBO 128 MTX+HCQ 128 1 T2T Remission-induction strategy (either combination csDMARD based strategy or bDMARD based strategy) versus single csDMARD-initiating strategy with GC bridging Akdemir, 2018 27 2 RCT 54 (14) 69 63 1.5 (0.7) 20 ( § ) 4.3 (0.8)** MTX+GC 175 MTX+SSZ+GC 133 1 T2T bridg. 34w De Jong, 2014 28 RCT 54 (14) 68 71 1 (0.7) 24 (13) 3.4 (1.0)** MTX+GC 97 MTX+SSZ+HCQ+ GCim MTX+SSZ+HCQ+GC 91 93 1 T2T IM 80-120mg or bridg. 10w Nam, 2014a* 29 RCT 53 (13) 69 55 1.4 (0.5) 5 ( § ) 3.8 (1.0)** MTX+GCiv 57 MTX+INF 55 0.5 T2T IV 250mg Stouten, 2017 30 RCT § § § § § § MTX+GC 98 MTX+SSZ+GC MTX+LEF+GC 98 93 1 T2T bridg. 34w Ter Wee, 2015 31 RCT 52 (13) 69 59 1.4 (0.7) 24 (20) 5.4 (1.2) MTX+GC 81 MTX+SSZ+GC 81 1 T2T bridg. 34w Verschueren, 2017 32 Trial 52 (13) 71 58 1 (0.7) 3 (4) 4.7 (1.4) MTX+GC MTX 141 172 MTX+SSZ+GC MTX+LEF+GC 98 90 1 T2T bridg. 34w 2